India’s pharmaceutical marketing regulations are set for a fresh review, with the Union Government constituting a three-member committee to examine existing safeguards against unethical promotional practices and recommend ways to improve enforcement. The committee, led by a NITI Aayog member, includes a former Union health secretary and the chairman and managing director of a leading hospital group. It has been tasked with submitting its recommendations to the Department of Pharmaceuticals within two months of its first meeting, following consultations with stakeholders.

The review will assess the effectiveness of current monitoring, oversight, and enforcement mechanisms, with a focus on improving transparency, accountability, and compliance. The panel will also consider whether the existing framework requires stronger regulatory, statutory, or other legal provisions. At the heart of…